Serina Therapeutics (FRA:2BO) Total Stockholders Equity : €0.61 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Total Stockholders Equity?

Serina Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €0.61 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Serina Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was €0.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Serina Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.42.

Serina Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Serina Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Total Stockholders Equity Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

-31.07

-35.66

-29.61

0.61

Serina Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial					-29.61	-3.96	-15.20	-12.41	0.61

Serina Therapeutics (FRA:2BO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Serina Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0.612	-	0)	/	9.422
	=	0.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Serina Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.256)	/	0.612
	=	0.42

Serina Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (FRA:2BO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SER:USA

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Serina Therapeutics Headlines

No Headlines